DK3191476T3 - Tetrahydroquinolinderivater som bromdomænehæmmere. - Google Patents
Tetrahydroquinolinderivater som bromdomænehæmmere. Download PDFInfo
- Publication number
- DK3191476T3 DK3191476T3 DK15760461.2T DK15760461T DK3191476T3 DK 3191476 T3 DK3191476 T3 DK 3191476T3 DK 15760461 T DK15760461 T DK 15760461T DK 3191476 T3 DK3191476 T3 DK 3191476T3
- Authority
- DK
- Denmark
- Prior art keywords
- amino
- acetyl
- carboxamide
- dimethyl
- tetrahydroquinoline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (15)
1. Forbindelse udvalgt fra gruppen bestående af: l-acetyl-4-((5-chlorpyrimidin-2-yl)amino)-2-methyl-l,2,3,4-tetrahydroquinolin-6- carboxamid; l-acetyl-4-((5-cyanopyridin-2-yl)amino)-/V-ethyl-2,3-dimethyl-l,2,3,4-tetrahydroquinolin- 6-carboxamid; l-acetyl-4-((5-cyanopyridin-2-yl)amino)-2,3-dimethyl-l,2,3,4-tetrahydroquinolin-6- carboxamid; l-acetyl-4-((5-cyanopyridin-2-yl)amino)-2,3-dimethyl-/V-(tetrahydro-2/7-pyran-4-yl)- l,2,3,4-tetrahydroquinolin-6-carboxamid; l-acetyl-4-((5-cyanopyridin-2-yl)amino)-/V-((R)-2-hydroxypropyl)-2,3-dimethyl-l,2,3,4- tetrahydroquinolin-6-carboxamid; l-acetyl-4-((5-cyanopyridin-2-yl)amino)-/V-((S)-2-hydroxypropyl)-2,3-dimethyl-l,2,3,4- tetrahydroquinolin-6-carboxamid; l-acetyl-4-((5-chlorpyrimidin-2-yl)amino)-/V-ethyl-2,3-dimethyl-l,2,3,4- tetrahydroquinolin-6-carboxamid; l-acetyl-4-((5-chlorpyrimidin-2-yl)amino)-2,3-dimethyl-l,2,3,4-tetrahydroquinolin-6- carboxamid; l-acetyl-4-((5-chlorpyrimidin-2-yl)amino)-2,3-dimethyl-/V-(tetrahydro-2/7-pyran-4-yl)- l,2,3,4-tetrahydroquinolin-6-carboxamid; l-acetyl-4-((5-chlorpyrimidin-2-yl)amino)-/V-((S)-2-hydroxypropyl)-2,3-dimethyl-l,2,3,4- tetrahydroquinolin-6-carboxamid; l-acetyl-4-((5-chlorpyrimidin-2-yl)amino)-/V-((R)-2-hydroxypropyl)-2,3-dimethyl-l,2,3,4- tetrahydroquinolin-6-carboxamid; l-acetyl-4-((5-cyanopyrazin-2-yl)amino)-2,3-dimethyl-l,2,3,4-tetrahydroquinolin-6- carboxamid; l-acetyl-4-((5-cyanopyrazin-2-yl)amino)-/V-ethyl-2,3-dimethyl-l,2,3,4-tetrahydroquinolin- 6-carboxamid; l-acetyl-/V-ethyl-4-((5-fluorpyridin-2-yl)amino)-2,3-dimethyl-l,2,3,4-tetrahydroquinolin-6- carboxamid; l-acetyl-4-((5-chlorpyrimidin-2-yl)amino)-/V-ethyl-2-methyl-l,2,3,4-tetrahydroquinolin-6-carboxamid; og l-acetyl-4-((5-cyanopyridin-2-yl)amino)-/V-ethyl-2-methyl-l,2,3,4-tetrahydroquinolin-6- carboxamid eller et salt deraf.
2. Forbindelse ifølge krav 1 udvalgt fra gruppen bestående af: (2S,3R,4R)-l-acetyl-4-((5-cyanopyridin-2-yl)amino)-/V-ethyl-2,3-dimethyl-l,2,3,4-tetrahydroquinolin-6-carboxamid; (2S,3R,4R)-l-acetyl-4-((5-cyanopyridin-2-yl)amino)-2,3-dimethyl-l,2,3,4- tetrahydroquinolin-6-carboxamid; (2S,3R,4R)-l-acetyl-4-((5-cyanopyridin-2-yl)amino)-2,3-dimethyl-/V-(tetrahydro-2/7- pyran-4-yl)-l,2,3,4-tetrahydroquinolin-6-carboxamid; (2S,3R,4R)-l-acetyl-4-((5-cyanopyridin-2-yl)amino)-/V-((R)-2-hydroxypropyl)-2,3- dimethyl-l,2,3,4-tetrahydroquinolin-6-carboxamid; (2S,3R,4R)-l-acetyl-4-((5-cyanopyridin-2-yl)amino)-/V-((S)-2-hydroxypropyl)-2,3- dimethyl-l,2,3,4-tetrahydroquinolin-6-carboxamid; (2S,3R,4R)-l-acetyl-4-((5-chlorpyrimidin-2-yl)amino)-/V-ethyl-2,3-dimethyl-l,2,3,4- tetrahydroquinolin-6-carboxamid; (2S,3R,4R)-l-acetyl-4-((5-chlorpyrimidin-2-yl)amino)-2,3-dimethyl-l,2,3,4- tetrahydroquinolin-6-carboxamid; (2S,3R,4R)-l-acetyl-4-((5-chlorpyrimidin-2-yl)amino)-2,3-dimethyl-/V-(tetrahydro-2/7- pyran-4-yl)-l,2,3,4-tetrahydroquinolin-6-carboxamid; (2S,3R,4R)-l-acetyl-4-((5-chlorpyrimidin-2-yl)amino)-/V-((S)-2-hydroxypropyl)-2,3- dimethyl-l,2,3,4-tetrahydroquinolin-6-carboxamid; (2S,3R,4R)-l-acetyl-4-((5-chlorpyrimidin-2-yl)amino)-/V-((R)-2-hydroxypropyl)-2,3- dimethyl-l,2,3,4-tetrahydroquinolin-6-carboxamid; (2S,3R,4R)-l-acetyl-4-((5-cyanopyrazin-2-yl)amino)-2,3-dimethyl-l,2,3,4- tetrahydroquinolin-6-carboxamid; (2S,3R,4R)-l-acetyl-4-((5-cyanopyrazin-2-yl)amino)-/V-ethyl-2,3-dimethyl-l,2,3,4- tetrahydroquinolin-6-carboxamid; (2S,3R,4R)-l-acetyl-/V-ethyl-4-((5-fluorpyridin-2-yl)amino)-2,3-dimethyl-l,2,3,4- tetrahydroquinolin-6-carboxamid; (2S,4R)-l-acetyl-4-((5-chlorpyrimidin-2-yl)amino)-/V-ethyl-2-methyl-l,2,3,4- tetrahydroquinolin-6-carboxamid; og (2S,4R)-l-acetyl-4-((5-cyanopyridin-2-yl)amino)-/V-ethyl-2-methyl-l,2,3,4- tetrahydroquinolin-6-carboxamid eller et salt deraf.
3. Forbindelse ifølge krav 1, som er (2S,4R)-l-acetyl-4-((5-chlorpyrimidin-2-yl)amino)-2-methyl-l,2,3,4-tetrahydroquinolin-6-carboxamid
eller et salt deraf.
4. Forbindelse ifølge et hvilket som helst af kravene 1-3, eller et farmaceutisk acceptabelt salt deraf.
5. Forbindelse ifølge et hvilket som helst af kravene 1 - 3 i form af en fri base.
6. Farmaceutisk sammensætning, som omfatter en forbindelse eller et farmaceutisk
acceptabelt salt deraf som defineret i krav 4 og et eller flere farmaceutisk acceptable bærestoffer, fortyndingsmidler eller excipienser.
7. Kombinationsprodukt omfattende en forbindelse eller et farmaceutisk acceptabelt salt deraf som defineret i krav 4, sammen med et eller flere andre terapeutisk virksomme midler.
8. Forbindelse eller et farmaceutisk acceptabelt salt deraf som defineret i krav 4 til anvendelse i terapi.
9. Forbindelse eller et farmaceutisk acceptabelt salt deraf som defineret i krav 4, til anvendelse i behandling af sygdomme eller tilstande, hvor en bromdomænehæmmer er indikeret.
10. Forbindelse eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 9, hvor sygdommen eller tilstanden er en akut eller kronisk autoimmun og/eller inflammatorisk tilstand.
11. Forbindelse eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 10, hvor den akutte eller kroniske autoimmune og/eller inflammatoriske tilstand eller sygdom er leddegigt.
12. Forbindelse eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 9, hvor sygdommen eller tilstanden involverer en inflammatorisk reaktion på en infektion med bakterier, en virus, svampe, en parasit eller deres toksiner.
13. Forbindelse eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 9, hvor sygdommen eller tilstanden er en virusinfektion.
14. Forbindelse eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 9, hvor sygdommen eller tilstanden er cancer.
15. Forbindelse eller et farmaceutisk acceptabelt salt deraf til anvendelse ifølge krav 14, hvor canceren er udvalgt blandt hæmatologiske epitel- inklusiv lunge-, bryst- og tyktarms-carcinomer, midtlinjecarcinomer, mesenkym-, lever-, nyre- og neurologiske tumorer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462049449P | 2014-09-12 | 2014-09-12 | |
| PCT/EP2015/070665 WO2016038120A1 (en) | 2014-09-12 | 2015-09-09 | Tetrahydroquinoline derivatives as bromodomain inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3191476T3 true DK3191476T3 (da) | 2019-01-14 |
Family
ID=54065889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15760461.2T DK3191476T3 (da) | 2014-09-12 | 2015-09-09 | Tetrahydroquinolinderivater som bromdomænehæmmere. |
Country Status (35)
| Country | Link |
|---|---|
| US (1) | US10059699B2 (da) |
| EP (1) | EP3191476B1 (da) |
| JP (1) | JP6531167B2 (da) |
| KR (1) | KR20170054421A (da) |
| CN (1) | CN106687453B (da) |
| AR (1) | AR101806A1 (da) |
| AU (1) | AU2015314184B2 (da) |
| BR (1) | BR112017004580A2 (da) |
| CA (1) | CA2958159A1 (da) |
| CL (1) | CL2017000587A1 (da) |
| CO (1) | CO2017001601A2 (da) |
| CR (1) | CR20170090A (da) |
| CY (1) | CY1121369T1 (da) |
| DK (1) | DK3191476T3 (da) |
| DO (1) | DOP2017000058A (da) |
| EA (1) | EA031679B9 (da) |
| ES (1) | ES2705623T3 (da) |
| HR (1) | HRP20182064T1 (da) |
| HU (1) | HUE041694T2 (da) |
| IL (1) | IL250397A0 (da) |
| LT (1) | LT3191476T (da) |
| MA (1) | MA40366A (da) |
| MX (1) | MX2017003219A (da) |
| PE (1) | PE20170675A1 (da) |
| PH (1) | PH12017500348A1 (da) |
| PL (1) | PL3191476T3 (da) |
| PT (1) | PT3191476T (da) |
| RS (1) | RS58135B1 (da) |
| SG (1) | SG11201701043UA (da) |
| SI (1) | SI3191476T1 (da) |
| TR (1) | TR201820050T4 (da) |
| TW (1) | TWI686389B (da) |
| UY (1) | UY36292A (da) |
| WO (1) | WO2016038120A1 (da) |
| ZA (1) | ZA201700883B (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA029052B1 (ru) | 2013-03-14 | 2018-02-28 | Бёрингер Ингельхайм Интернациональ Гмбх | Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с |
| WO2016038007A1 (en) | 2014-09-12 | 2016-03-17 | Boehringer Ingelheim International Gmbh | Spirocyclic inhibitors of cathepsin c |
| US11028051B2 (en) | 2016-12-13 | 2021-06-08 | St. Jude Children's Research Hospital | Tetrahydroquinoline-based bromodomain inhibitors |
| WO2020092638A1 (en) | 2018-10-30 | 2020-05-07 | Nuvation Bio Inc. | Heterocyclic compounds as bet inhibitors |
| KR20220028072A (ko) | 2019-07-02 | 2022-03-08 | 누베이션 바이오 인크. | Bet 억제제로서의 헤테로시클릭 화합물 |
| EP4095128A1 (en) | 2021-05-25 | 2022-11-30 | Centre national de la recherche scientifique | Tetrahydroquinoline (thq) coumpounds |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010113498A1 (ja) * | 2009-03-31 | 2010-10-07 | 興和株式会社 | テトラヒドロキノリン化合物を有効成分とする貧血の予防及び／又は治療剤 |
| GB0919431D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB0919432D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Use |
| GB0919434D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| GB201106743D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201106750D0 (en) | 2011-04-21 | 2011-06-01 | Glaxosmithkline Llc | Novel compounds |
| GB201107325D0 (en) | 2011-05-04 | 2011-06-15 | Glaxosmithkline Llc | Novel compounds |
| MX369324B (es) * | 2013-03-14 | 2019-11-05 | Glaxosmithkline Ip No 2 Ltd | Derivados de 1-acil-4-amino-1,2,3,4-tetrahidroquinolina 2,3-disustituidos y su uso como inhibidores de bromodominio. |
-
2015
- 2015-09-09 PT PT15760461T patent/PT3191476T/pt unknown
- 2015-09-09 EP EP15760461.2A patent/EP3191476B1/en active Active
- 2015-09-09 PL PL15760461T patent/PL3191476T3/pl unknown
- 2015-09-09 RS RS20190001A patent/RS58135B1/sr unknown
- 2015-09-09 JP JP2017513723A patent/JP6531167B2/ja not_active Expired - Fee Related
- 2015-09-09 CN CN201580048713.8A patent/CN106687453B/zh not_active Expired - Fee Related
- 2015-09-09 HU HUE15760461A patent/HUE041694T2/hu unknown
- 2015-09-09 CR CR20170090A patent/CR20170090A/es unknown
- 2015-09-09 US US15/509,894 patent/US10059699B2/en active Active
- 2015-09-09 ES ES15760461T patent/ES2705623T3/es active Active
- 2015-09-09 DK DK15760461.2T patent/DK3191476T3/da active
- 2015-09-09 SG SG11201701043UA patent/SG11201701043UA/en unknown
- 2015-09-09 EA EA201790484A patent/EA031679B9/ru not_active IP Right Cessation
- 2015-09-09 BR BR112017004580-0A patent/BR112017004580A2/pt not_active Application Discontinuation
- 2015-09-09 MX MX2017003219A patent/MX2017003219A/es active IP Right Grant
- 2015-09-09 PE PE2017000388A patent/PE20170675A1/es unknown
- 2015-09-09 LT LTEP15760461.2T patent/LT3191476T/lt unknown
- 2015-09-09 MA MA040366A patent/MA40366A/fr unknown
- 2015-09-09 CA CA2958159A patent/CA2958159A1/en not_active Abandoned
- 2015-09-09 KR KR1020177008675A patent/KR20170054421A/ko unknown
- 2015-09-09 WO PCT/EP2015/070665 patent/WO2016038120A1/en active Application Filing
- 2015-09-09 AU AU2015314184A patent/AU2015314184B2/en not_active Ceased
- 2015-09-09 TR TR2018/20050T patent/TR201820050T4/tr unknown
- 2015-09-09 SI SI201530529T patent/SI3191476T1/sl unknown
- 2015-09-10 AR ARP150102888A patent/AR101806A1/es unknown
- 2015-09-10 UY UY0001036292A patent/UY36292A/es not_active Application Discontinuation
- 2015-09-10 TW TW104129977A patent/TWI686389B/zh not_active IP Right Cessation
-
2017
- 2017-02-01 IL IL250397A patent/IL250397A0/en unknown
- 2017-02-03 ZA ZA2017/00883A patent/ZA201700883B/en unknown
- 2017-02-17 CO CONC2017/0001601A patent/CO2017001601A2/es unknown
- 2017-02-27 PH PH12017500348A patent/PH12017500348A1/en unknown
- 2017-03-07 DO DO2017000058A patent/DOP2017000058A/es unknown
- 2017-03-09 CL CL2017000587A patent/CL2017000587A1/es unknown
-
2018
- 2018-12-06 HR HRP20182064TT patent/HRP20182064T1/hr unknown
-
2019
- 2019-01-15 CY CY20191100049T patent/CY1121369T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2970127T3 (da) | 2,3-disubstituerede 1-acyl-4-amino-1,2,3,4-tetrahydroquinolinderivater og anvendelse deraf som bromdomænehæmmere | |
| DK3191476T3 (da) | Tetrahydroquinolinderivater som bromdomænehæmmere. | |
| US9670221B2 (en) | Furopyridines as bromodomain inhibitors | |
| DK2744809T3 (da) | 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazol og anvendelse deraf som bromodomæneinhibitor | |
| US9663533B2 (en) | Thieno[3,2-C]pyridin-4(5H)-ones as BET inhibitors | |
| US10927080B2 (en) | Pyridinone dicarboxamide for use as bromodomain inhibitors | |
| US10370356B2 (en) | Pyridinone dicarboxamide for use as bromodomain inhibitors | |
| CN108290866B (zh) | 作为溴结构域抑制剂的2-氧代-1,2-二氢吡啶-3,5-二甲酰胺化合物 | |
| CN108884070B (zh) | 作为溴结构域抑制剂的吡啶基衍生物 | |
| IL268565A (en) | History of pyrazole as bromodomain inhibitors | |
| US10849897B2 (en) | Pyridyl derivatives as bromodomain inhibitors | |
| WO2016062737A1 (en) | 1,3-dimethylbenzimidazolone derivative as an inhibitor of the brpf1 bromodomain |